Product
WX390
Aliases
WXFL10030390
Name
WX390
4 clinical trials
3 indications
Indication
Solid TumorIndication
PIK3CA Mutation-Related TumorsClinical trial
A Phase Ib/IIa Study to Evaluate the Safety and Preliminary Efficacy of WX390 Combined With Toripalimab in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase II Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 MutationsStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase Ib/IIa Study to Evaluate the Safety and Preliminary Efficacy of WX390, a PI3K/mTOR Dual Inhibitor, for the Treatment of Advanced Solid Tumors With PIK3CA MutationsStatus: Completed, Estimated PCD: 2023-01-03
Clinical trial
An Open-label, Single-arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of WX390 in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-06-01